Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 5,201–5,300 of 15,747
Benefit–risk evaluation of COVID-19 vaccination in special population groups of interest
Moss, P. A. H., Berenbaum, F., Curigliano, G., Grupper, A., Berg, T., & Pather, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.067 · Cited by 18
Rabdano, S. O., Ruzanova, E., Vertyachikh, A. E., Teplykh, V. A., Emelyanova, A. B., Rudakov, G. O., Arakelov, S. A., Pletyukhina, I. V., Saveliev, N. S., Lukovenko, A. A., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106288 · Cited by 22
Nanomedicine-based strategies for the treatment of vein graft disease
Zhou, Z., Chen, W., Cao, Y., Abdi, R., & Tao, W. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01094-y · Cited by 21
“Remarkably, the successes of COVID-19 mRNA vaccines (BNT162b2 by Pfizer and mRNA-1273 by Moderna) underscores the clinical potential of mRNA-based nanotechnology 210,211 .”
Hoste, A. C. R., Smeralda, W., Cugnet, A., Brostaux, Y., Deleu, M., Garigliany, M., & Jacques, P. (2024) · Applied and Environmental Microbiology · doi:10.1128/aem.01036-24 · Cited by 19
Brunelli, S. M., Sibbel, S., Karpinski, S., Marlowe, G., Walker, A. G., Giullian, J., Wyck, D. V., Kelley, T., Lazar, R., Zywno, M. L., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021101395 · Cited by 18
Kremsner, P. G., Guerrero, R. A. A., Arana, E., Aroca Martinez, G. J., Bonten, M. J. M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., et al. (2021) · doi:10.2139/ssrn.3911826 · Cited by 17
Ha, J., Park, S., Kang, H., Kyung, T., Kim, N., Kim, D., Kim, H., Bae, K., Song, M. C., Lee, K. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-30940-1 · Cited by 21
Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study
Duan, Y., Luo, J., Zhao, L., Zhang, X., Miao, J., Moher, D., & Bian, Z. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103962 · Cited by 18
Filon, F. L., Rui, F., Ronchese, F., Michieli, P. D., & Negro, C. (2022) · Scientific Reports · doi:10.1038/s41598-021-04665-y · Cited by 19
Li, X., Wichai, N., Wang, J., Liu, X., Yan, H., Wang, Y., Luo, M., Zhou, S., Wang, K., Lin, L., et al. (2022) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000046 · Cited by 18
The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients
Dęborska−Materkowska, D., & Kamińska, D. (2021) · Viruses · doi:10.3390/v13091879 · Cited by 18
DNA-terminus-dependent transcription by T7 RNA polymerase and its C-helix mutants
Yu, B., Chen, Y., Yan, Y., Lu, X., & Zhu, B. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae593 · Cited by 21
Ricciardi, A., Zelini, P., Cassaniti, I., Avanzini, M. A., Colaneri, M., SILVESTRI, A. D., Baldanti, F., & Bruno, R. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.06.055 · Cited by 18
Chu, E. C. (2022) · Medical Science Monitor · doi:10.12659/msm.937430 · Cited by 17
“Millions of doses of the Coronavirus 2019 (COVID-19) vaccine have been widely administered with efficacy in combating the COVID-19 pandemic [1].”
BackgroundHalder, U. C. (2021) · Journal of Biological Research - Thessaloniki · doi:10.1186/s40709-021-00149-2 · Cited by 16
“Great efforts were carried out by the scientists to develop potent vaccines like Astrazeneca/Oxford [1], Johnson & Johnson [2], Moderna [3], Pfizer/BionTech [4], Sinopharm, Sinovac [5], and COVISHIELD [6], having the potential to curb human mortality.”
BackgroundChoi, M. J., Choi, W. S., Seong, H., et al. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e166 · Cited by 17
Detection, prevention and treatment of COVID‐19 and opportunities for nanobiotechnology
Bao, Q., Yang, T., Yang, M., & Mao, C. (2022) · View · doi:10.1002/viw.20200181 · Cited by 16
Haase, M., Lesny, P., Anderson, M., Cloherty, G., Stec, M., Haase‐Fielitz, A., Haarhaus, M. L., Santos-Araújo, C., Veiga, P. M., & Macario, F. J. G. R. M. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01247-7 · Cited by 18
“There is strong evidence that vaccination of the normal population with approved SARS-CoV-2-vaccines is safe and provides effective protection against SARS-CoV-2 [1, 2].”
BackgroundSensitivity theorems of a model of multiple imperfect vaccines for COVID-19
Aguilar-Canto, F. J., de León, U. A.-P., & Avila-Vales, E. J. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.111844 · Cited by 19
Ellul, P., Revés, J., Abreu, B., Chaparro, M., Gisbert, J. P., Allocca, M., Fiorino, G., Barberio, B., Zingone, F., Pisani, A., et al. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac010 · Cited by 19
“The promising clinical trials and subsequent roll-out of the BNT162b2 (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), mRNA-1273 (Moderna) and JNJ-78436735 (Johnson and Johnson) vaccines have heralded a step towards the control of the pandemic.(2-4).”
BackgroundResultInfluentialCOVID-19 vaccines and vaccine administration
Gordon, C., Porteous, D., & Unsworth, J. (2021) · British Journal of Nursing · doi:10.12968/bjon.2021.30.6.344 · Cited by 15
Law, M. F., Ho, R., Law, K. W. T., & Cheung, C. K. M. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i12.1850 · Cited by 24
Wilta, F., Chong, A. L. C., Selvachandran, G., Kotecha, K. V., & Ding, W. (2022) · Applied Soft Computing · doi:10.1016/j.asoc.2022.108973 · Cited by 19
Oberemok, V. V., Andreeva, O. A., Laikova, K. V., Novikov, I. A., & Kubyshkin, A. V. (2022) · Inflammation Research · doi:10.1007/s00011-022-01582-2 · Cited by 17
“People who received mRNA vaccines reported hearing impairment, exacerbation of asthma, bloating, rosacea, and skin sensitivity disorders [9, 10], while those who received adenovirus vaccines reported laryngeal and facial edema, thrombosis, anemia, thrombocytopenia [11], nausea, and swollen lymph nodes [12].”
BackgroundSieling, P. A., King, T. B., Wong, R. M. H., Nguyen, A., Wnuk, K., Gabitzsch, E., Rice, A., Adisetiyo, H., Hermreck, M., Verma, M., et al. (2021) · medRxiv · doi:10.1101/2021.04.05.21254940 · Cited by 21
Development of facial palsy following COVID-19 vaccination: A systematic review
Khurshid, M., Ansari, I., Ahmad, H., Ghaffar, H., Khurshid, A., Shahid, A., Essar, M. Y., Ullah, I., & Cheema, H. A. (2022) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2022.104758 · Cited by 22
Operational challenges in the COVID‐19 era: Asymptomatic infections and vaccination timing
Axelrod, D. A., İnce, D., Harhay, M. N., et al. (2021) · Clinical Transplantation · doi:10.1111/ctr.14437 · Cited by 17
Rose, A., Nicolay, N., Martín, V. S., Mazagatos, C., Petrović, G., Baruch, J., Denayer, S., Seyler, L., Domegan, L. M., Launay, O., et al. (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.47.2300187 · Cited by 18
Mutations Associated with SARS-CoV-2 Variants of Concern, Benin, Early 2021
Sander, A., Yadouléton, A., de Oliveira-Filho, E. F., Tchibozo, C., Hounkanrin, G., Badou, Y., Adewumi, P., René, K. K., Ange, D., Salifou, S., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2711.211353 · Cited by 17
Sood, A., Tran, M., Murthy, V., & González, E. B. (2022) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001871 · Cited by 22
Decisive conditions for strategic vaccination against SARS-CoV-2
Böttcher, L., & Nagler, J. (2021) · Chaos An Interdisciplinary Journal of Nonlinear Science · doi:10.1063/5.0066992 · Cited by 15
Cozzolino, A., Hasenmajer, V., Newell-Price, J. D. C., & Isidori, A. M. (2023) · Endocrine · doi:10.1007/s12020-023-03411-w · Cited by 19
“The most common side effects of mRNA vaccines are pain for several days at the injection site, fatigue, headache, myalgias, arthralgias, chills, and fever [64, 65], and all of these signs and symptoms can early indicate an increased need for GC replacement therapy in patients with AI [66].”
Tedeschi, S. K., Ellrodt, J., Stratton, J., Santacroce, L. M., Chandler, P. D., Gravallese, E. M., & Solomon, D. H. (2021) · ACR Open Rheumatology · doi:10.1002/acr2.11351 · Cited by 16
Katz, M. A., Bron‐Harlev, E., Chazan, B., Chowers, M., Greenberg, D., Peretz, A., Tshori, S., Levy, J., Yacobi, M., Hirsch, A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.092 · Cited by 19
“While clinical trials [2] and real-world effectiveness studies [3] have demonstrated the effectiveness of Covid-19 vaccines in preventing SARS-CoV-2 infections, most of these studies were not designed to accurately assess the extent by which vaccines reduce asymptomatic infection, a modality that has been shown to pla…”
BackgroundSu, D., Li, X., He, C., Huang, X., Chen, M., Wang, Q., Qin, W., Liang, Y. S., Xu, R., Wu, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.16.444369 · Cited by 17
Course and Lethality of SARS-CoV-2 Epidemic in Nursing Homes after Vaccination in Florence, Italy
Rivasi, G., Bulgaresi, M., Mossello, E., et al. (2021) · Vaccines · doi:10.3390/vaccines9101174 · Cited by 17
“The results of pivotal clinical trials have demonstrated near 95% effectiveness of the BNT162b2 mRNA vaccine in preventing symptomatic COVID-19, with new SARS-CoV-2 infections starting to decrease as early as two weeks after the administration of the first dose (52% effectiveness), corresponding to the time at which t…”
ResultFor the Passive Immunity Trial for Our Nation (PassITON) Investigators, Self, W. H., Stewart, T. G., Wheeler, A. P., Atrouni, W. E., Bistran-Hall, A. J., Casey, J. D., Cataldo, V. D., Chappell, J. D., Cohn, C. S., et al. (2021) · Trials · doi:10.1186/s13063-021-05171-2 · Cited by 19
Cotugno, N., Franzese, E., Angelino, G., Amodio, D., Romeo, E. F., Rea, F., Faraci, S., Tambucci, R., Profeti, E., Manno, E. C., et al. (2022) · Vaccines · doi:10.3390/vaccines10071109 · Cited by 19
“[26] were reported to the unit of occupational medicine by the employees enrolled.”
BackgroundIL-7 promotes mRNA vaccine-induced long-term immunity
Wang, L., Wan, J., He, W., Wang, Z., Wu, Q. D., Zhou, M., Fu, Z. F., & Zhao, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02993-5 · Cited by 18
Rouphael, N., & Bausch-Jurken, M. T. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad162 · Cited by 18
“The phase 2 and 3 clinical studies of mRNA-based COVID-19 vaccines [18, 19] did not include patients receiving maintenance dialysis; however, the immunogenicity of 2 doses of mRNA-based vaccines in this population has been characterized in several smaller observational studies.”
BackgroundSalimian, J., Ahmadi, A., Amani, J., Olad, G., Halabian, R., Saffaei, A., Arabfard, M., Nasiri, M., Nazarian, S., Abolghasemi, H., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28097 · Cited by 18
“The BNT162b2, an RBD‐based COVID‐19 vaccine candidate, showed good immunogenicity results in healthy volunteers.(29) Other vaccines such as NovoVax and Zhifei are other RBD‐based vaccines that have shown considerable immunogenicity.”
BackgroundRetractedHein, S., Mhedhbi, I., Zahn, T. R., Sabino, C., Benz, N. I., Husria, Y., Renelt, P. M., Braun, F., Oberle, D., Maier, T. J., et al. (2022) · Vaccines · doi:10.3390/vaccines10050796 · Cited by 17
“Real-world data revealed for the mRNA vaccines (mRNA-1273 and BNT162b2) a very high vaccine effectiveness of more than 90% with respect to the prevention of COVID-19 [14,15].”
BackgroundInfluentialOptimal Social Distancing Policy for COVID-19 Control in Korea: A Model-Based Analysis
Jo, Y., Shrestha, S., Radnaabaatar, M., Park, H., & Jung, J. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e189 · Cited by 20
Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries
Siedner, M., Alba, C., Fitzmaurice, K., Gilbert, R., Scott, J. A., Shebl, F. M., Ciaranello, A. L., Reddy, K. P., & Freedberg, K. (2021) · medRxiv · doi:10.1101/2021.04.28.21256237 · Cited by 18
Post COVID-19 vaccination headache: A clinical and epidemiological evaluation
Ceccardi, G., di Cola, F. S., Cesare, M. D., Liberini, P., Magoni, M., Perani, C., Gasparotti, R., Rao, R., & Padovani, A. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.994140 · Cited by 20
Perioperative Coronavirus Vaccination—Timing and Implications: A Guidance Document
Merritt-Genore, H., Moosdorf, R., Gillaspie, E. A., Lother, S., Engelman, D. T., Ahmed, S., Baciewicz, F. A., Grant, M. C., Milewski, R. C. K., Cawcutt, K. A., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.07.016 · Cited by 20
“As of early June 2021 there were 102 vaccines in phase I to III trials and 185 under investigation in preclinical studies, whereas 3 COVID-19 vaccines had received US Food and Drug Administration Emergency Use Approval.(21-25,31) One additional vaccine is currently in use in Europe, Canada, Asia, and Latin America, an…”
InfluentialLicensed liposomal vaccines and adjuvants in the antigen delivery system
Krasnopolsky, Y., & Pylypenko, D. (2022) · Biotechnologia · doi:10.5114/bta.2022.120709 · Cited by 24
“According to the current data, 94% fewer cases of infection symptoms are reported in patients vaccinated against COVID-19 than in unvaccinated people in a control group (Cheng et al., 2021; Polack et al., 2020).”
BackgroundNaseem‐Khan, S., Berger, M. B., Leddin, E. M., Maghsoud, Y., & Cisneros, G. A. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00201 · Cited by 18
Dinas, P. C., Koutedakis, Y., Ioannou, L. G., Metsios, G. S., & Kitas, G. D. (2022) · Vaccines · doi:10.3390/vaccines10050769 · Cited by 23
“Antibody responses to bacterial and viral vaccines are thought to be usually higher in females than males [86,87], although it is notable that when a total of 43,548 participants underwent randomization for vaccination with the Pfizer/Biontech COVID-19 vaccine, BNT162b2 (21,728 with placebo), similar vaccine efficacy…”
BackgroundCOVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective
Cavaillon, J.-M., & Osuchowski, M. F. (2021) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2021.04.003 · Cited by 17
“[93] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
Bell’s palsy following COVID-19 vaccination: a case report
Caro, G. G. D. T., Díaz, S. G., Alé, M. P., & Martínez‐Gimeno, M. L. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2021.04.002 · Cited by 16
SARS-CoV-2: Outline, Prevention, and Decontamination
Janik, E., Bartos, M., Niemcewicz, M., Gorniak, L., & Bijak, M. (2021) · Pathogens · doi:10.3390/pathogens10020114 · Cited by 22
Vaccines Against COVID-19: A Review
Torres-Estrella, C. U., Reyes-Montes, M. D. R., Duarte-Escalante, E., Sierra-Martínez, M., León, M. G. F.-D., & Acosta‐Altamirano, G. (2022) · Vaccines · doi:10.3390/vaccines10030414 · Cited by 19
Bio-safety and bio-security: A major global concern for ongoing COVID-19 pandemic
Shehri, S. A. A., Alsulaiman, A. M., Azmi, S., & Alshehri, S. S. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.08.060 · Cited by 20
“In clinical trial phase III, these candidate vaccines have shown different levels of efficacy varying from 65% to 95% (Polack et al., 2020; Knoll and Wonodi, 2021).”
Rooney, A., Bivona, C. R., Liu, B., Streeter, D., Gong, H., & Khan, Q. J. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01290-8 · Cited by 18
“To the editor, Both the BNT162b2 (BioNTech, Pfizer) and mRNA1273 (Moderna) vaccines have established efficacy for preventing severe SARS-CoV-2 infection [1, 2].”
BackgroundKode, J., Maharana, J., Dar, A. A., Mukherjee, S., Gadewal, N., Sigalapalli, D. K., Kumar, S., Panda, D., Ghosh, S., Keshry, S. S., et al. (2023) · ACS Omega · doi:10.1021/acsomega.2c07138 · Cited by 18
Ruiz, P. L., Gunnes, N., Gran, J. M., Karlstad, Ø., Selmer, R. M., Dahl, J., Bøås, H., White, R. A., Hofman, A. C., Paulsen, T. H., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.085 · Cited by 20
“[6] Vaccine safety with respect to all-cause mortality has been studied in the clinical trials, but the reporting period has not been specified.[4].”
Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
Das, R., Hyer, R. N., Burton, P. B. J., Miller, J. M., & Kuter, B. J. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2153532 · Cited by 20
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Marchevsky, N. G., Li, G., Aley, P., Costa Clemens, S. A., Barrett, J. R., Belij-Rammerstorfer, S., Bibi, S., Clutterbuck, E., Dold, C., Felle, S., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104128 · Cited by 17
Haq, H. N., Khan, H., Chaudhry, H., Nimmala, S., Demidovich, J., Papudesi, B. N., & Potluri, S. D. (2022) · Journal of the National Medical Association · doi:10.1016/j.jnma.2022.08.003 · Cited by 22
Akhter, S., Berchel, M., Jaffrès, P., Midoux, P., & Pichon, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030581 · Cited by 20
Rabinowitz, K. M., Navon, M., Edelman-Klapper, H., Zittan, E., Shitrit, A. B., Goren, I., Avni‐Biron, I., Ollech, J. E., Lichtenstein, L., Banai-Eran, H., et al. (2022) · Vaccines · doi:10.3390/vaccines10081186 · Cited by 23
“This is specifically concerning during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which led to the use of new vaccines [7,8].”
BackgroundRunnstrom, M. C., Lamothe, P. A., Faliti, C. E., Cheedarla, N., Moreno, A., Suthar, M. S., Nahata, R., Ravindran, M., Haddad, N. S., Morrison-Porter, A., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.03.029 · Cited by 18
Kim, G. N., Choi, J.-A., Wu, K., Saeedian, N., Yang, E., Park, H., Woo, S., Lim, G., Kim, S.-G., Eo, S.-K., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010092 · Cited by 20
Buckley, J. E., Landis, L. N., & Rapini, R. P. (2022) · JAAD International · doi:10.1016/j.jdin.2022.01.009 · Cited by 17
“The mean reported age was 23 years, and the average time to onset from vaccination was 17 days.(16) The pathogenic mechanism of PR after vaccination is unknown.”
Lim, S. H., Choi, S.-H., Kim, B., Kim, J., Ji, Y.-S., Kim, S., Kim, C. K., Kim, T., Choo, E. J., Moon, J. E., et al. (2021) · Vaccines · doi:10.3390/vaccines9121379 · Cited by 16
“This lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encodes a prefusion-stabilized, membrane-anchored SARS-CoV-2 full-length spike protein [4].”
BackgroundMethodInfluentialKhateeb, D. M., Gabrieli, T., Sofer, B., Hattar, A., Cordela, S., Chaouat, A. E., Spivak, I., Lejbkowicz, I., Almog, R., Mandelboim, M., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010242 · Cited by 16
“Thus far, mRNA-based vaccines were highly effective in preventing SARS-CoV-2 infection and cases of SARS-CoV-2 infection in vaccinated individuals are relatively scarce [41].”
BackgroundInhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs
Maheden, K., Todd, B., Gordon, C. J., Tchesnokov, E. P., & Götte, M. (2021) · The Enzymes · doi:10.1016/bs.enz.2021.07.002 · Cited by 20
The Post-Acute COVID-19-Vaccination Syndrome in the Light of Pharmacovigilance
Platschek, B., & Boege, F. (2024) · Vaccines · doi:10.3390/vaccines12121378 · Cited by 24
“In the Comirnaty phase III study [22], the reactogenicity adverse events were mostly evolving within the first two days after application of the vaccine and subsided shortly thereafter.”
InfluentialQuantification of mRNA in Lipid Nanoparticles Using Mass Spectrometry
Lowenthal, M. S., Antonishek, A. S., & Phinney, K. W. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c04406 · Cited by 19
Long‐term effects of Pfizer‐BioNTech COVID‐19 vaccinations on platelets
Zhou, Y., Nishikawa, M., Kanno, H., Yang, R., Ibayashi, Y., Xiao, T., Peterson, W., Herbig, M., Nitta, N., Miyata, S., et al. (2022) · Cytometry Part A · doi:10.1002/cyto.a.24677 · Cited by 19
“the vaccination indicated by expected changes in the lymphocyte and monocyte counts (Figure 2C) [1, 2, 4, 5], these platelet aggregate data (Figure 2A,B), combined with small variations in the”
BackgroundResultO’Connor, M. A., Hawman, D. W., Meade-White, K. D., Leventhal, S. S., Song, W., Randall, S., Archer, J. F., Lewis, T. B., Brown, B., Fredericks, M., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011298 · Cited by 19
Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance
Jiménez-Cabello, L., Utrilla-Trigo, S., Barreiro-Piñeiro, N., Pose‐Boirazian, T., Martínez-Costas, J., Marín-López, A., & Ortego, J. (2022) · Vaccines · doi:10.3390/vaccines10071124 · Cited by 19
Salter, S. M., Li, D., Trentino, K. M., Nissen, L. M., Lee, K., Orlemann, K., Peters, I., Murray, K., Leeb, A., & Deng, L. (2022) · Vaccines · doi:10.3390/vaccines10122017 · Cited by 15
“We found similar proportions of AEFI after Pfizer dose 1 (26%) and 2 (31%), compared to a large study from Jordan (32% and 32%) [20], but substantially fewer AEFI compared to other post-marketing research (between 45–92%) [21–23], and phase 2/3 trials (between 66–83%) [24].”
ResultFryer, H. A., Hartley, G. E., Edwards, E. S. J., Varese, N. P., Boo, I., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O’Hehir, R. E., & van Zelm, M. C. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01527-2 · Cited by 14
“6, 69-71 Another factor that can influence the antibody response elicited by vaccines is anti-vector immunity, such as the generation of NAb specific for the adenovirus backbone component of ChAdOx1.”
BackgroundRichardson, J. R., Götz, R., Mayr, V., Lohse, M. J., Holthoff, H., & Ungerer, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266701 · Cited by 16
Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
Cheung, Y. Y. H., Lau, E. H. Y., Yin, G., Lin, Y., Cowling, B. J., & Lam, K. F. (2023) · Emerging infectious diseases · doi:10.3201/eid3001.230414 · Cited by 24
COVID-19 vaccination reduces mortality in patients on maintenance hemodialysis
Tylicki, L., Biedunkiewicz, B., Puchalska-Reglińska, E., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.937167 · Cited by 17
Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose
Filardi, B. A., Monteiro, V. S., Schwartzmann, P. V., Martins, V. D. P., Zucca, L. E. R., Baiocchi, G. C., Malik, A. A., Silva, J. D. S., Hahn, A. M., Chen, N. F. G., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade6023 · Cited by 16
Hetrick, B., Chilin, L. D., He, S., Dabbagh, D., Alem, F., Narayanan, A., Luchini, A., Li, T., Liu, X., Copeland, J., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100181 · Cited by 20
“…is available to reduce hospital stay (Beigel et al., 2020); several vaccines have recently shown significant results in phase III clinical trials (Jackson et al., 2020; Palacios et al., 2020; Polack et al., 2020; Ramasamy et al., 2021; Voysey et al., 2021) and been approved for emergency use.”
Transverse myelitis 48 hours after the administration of an mRNA COVID 19 vaccine
McLean, P., & Trefts, L. (2021) · Neuroimmunology Reports · doi:10.1016/j.nerep.2021.100019 · Cited by 17
Imhof, C., Messchendorp, A. L., van der Heiden, M., Baan, C. C., Molen, R. G. V. D., Remmerswaal, E. B. M., de Vries, R. D., Diavatopoulos, D. A., Boerma, A., Bakker, F. J., et al. (2022) · Transplantation Direct · doi:10.1097/txd.0000000000001387 · Cited by 17
Cohen, D. A., Greenberg, P., Formanowski, B., & Parikh, P. D. (2022) · Medicine · doi:10.1097/md.0000000000028839 · Cited by 19
Mitchell, J., Connolly, C. M., Chiang, T. P., Alejo, J. L., Werbel, W. A., Segev, D. L., & Massie, A. B. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.11897 · Cited by 15
Park, S., & Suh, Y. (2023) · Journal of Medical Internet Research · doi:10.2196/42623 · Cited by 16
Cubic Phase‐Inducible Zwitterionic Phospholipids Improve the Functional Delivery of mRNA
Iwakawa, K., Sato, R., Konaka, M., Yamada, Y., Harashima, H., & Sato, Y. (2025) · Advanced Science · doi:10.1002/advs.202413016 · Cited by 24
Tan, H., Yu, T., Liu, C., Wang, Y., Jing, F., Ding, Z., Liu, J., & Shi, H. (2022) · Cancer Medicine · doi:10.1002/cam4.4846 · Cited by 17
Safety Profile of COVID-19 Vaccines among Healthcare Workers in Poland
Paczkowska, A., Hoffmann, K., Michalak, M., Hans-Wytrychowska, A., Bryl, W., Kopciuch, D., Zaprutko, T., Ratajczak, P., Nowakowska, E., & Kus, K. (2022) · Vaccines · doi:10.3390/vaccines10030434 · Cited by 19
“The proportion of participants reporting local and systemic reactions did not increase after the second dose [23].”
BackgroundInfluentialThe initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
Zaqout, A., Daghfal, J., Alaqad, I., Hussein, S. A. N., Aldushain, A., Almaslamani, M., Abukhattab, M., & Omrani, A. S. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.021 · Cited by 17
Pan, H., Liu, J., Huang, B., Li, G., Chang, X., Liu, Y., Wang, W., Chu, K., Zhu, D., Wu, J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab627 · Cited by 21
“The safety, immunogenicity, and/or efficacy in human have been demonstrated and continued to be assessed in ongoing clinical trials for many of these vaccines [5-13].”
BackgroundGong, S. Y., Ding, S., Benlarbi, M., Chen, Y., Vézina, D., Marchitto, L., Beaudoin-Bussières, G., Goyette, G., Bourassa, C., Bo, Y., et al. (2022) · Viruses · doi:10.3390/v14102178 · Cited by 20
Wang, Z., Whittington, J. D., Yuan, H., Miao, H., Tian, H., & Stenseth, N. C. (2021) · Biosafety and Health · doi:10.1016/j.bsheal.2021.09.002 · Cited by 16
Marco, G. D., Giryes, S., Williams, K., Alcorn, N., Slade, M., Fitton, J. M., Nizam, S., Smithson, G., Iqbal, K., Tran, G. T., et al. (2022) · Vaccines · doi:10.3390/vaccines10081184 · Cited by 17
Feuchtenberger, M., Kovacs, M. S., Eder, A., Nigg, A. P., & Schäfer, A. (2022) · Rheumatology International · doi:10.1007/s00296-022-05123-2 · Cited by 20
Exciting Times for Lipid Nanoparticles: How Canadian Discoveries Are Enabling Gene Therapies
Cheng, M. H. Y., Brimacombe, C. A., Verbeke, R., & Cullis, P. R. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00365 · Cited by 19
The Challenges of Sustainable Development in Nigeria Amidst the Global Pandemic (COVID-19)
Abdulkadir, A. S., Saidu, S. A., Abdullahi, A., & Abdulkadir, F. (2022) · Journal of Law and Sustainable Development · doi:10.37497/sdgs.v10i1.206 · Cited by 18
“…BNT162b2, which was developed by BioNTech and manufactured and distributed by Pfizer and Fosun Pharmaceutical, has been authorized by a stringent regulatory authority for Emergency use in several countries including the USA (Airtable - Milken Institute, n.d.; Polack et al., 2020), and Nigeria.”
MethodInfluentialA Scenario-Based Evaluation of COVID-19-Related Essential Clinical Resource Demands in China
Zhang, T., Wang, Q., Leng, Z., Yang, Y., Yang, J., Chen, F., Jia, M., Zhang, X., Qi, W., Xu, Y., et al. (2021) · Engineering · doi:10.1016/j.eng.2021.03.020 · Cited by 16
“Based on various scenario assumptions, evaluated efficacy of the non-pharmaceutical interventions (NPIs) [3,4,26] and COVID-19 vaccines [27], and on a revised transmission dynamics model, this study aimed to assess clinical demands, using China as an example.”
MethodBhise, V. V., & Dhib-Jalbut, S. S. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01008-7 · Cited by 20
COVID-19 vaccine hesitancy in Sweden and Italy: The role of trust in authorities
Raffetti, E., Mondino, E., & Baldassarre, G. D. (2022) · Scandinavian Journal of Public Health · doi:10.1177/14034948221099410 · Cited by 25
“[5] Polack FP, Thomas SJ, Kitchin N, et al.”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.